×

Steve Hill

About Steve Hill

Steve serves on the LEAF Board of Directors and is the Editor in Chief, coordinating the daily news articles and social media content of the organization. He is an active journalist in the aging research and biotechnology field and has to date written over 600 articles on the topic, interviewed over 100 of the leading researchers in the field, hosted livestream events focused on aging, as well as attending various medical industry conferences. His work has been featured in H+ magazine, Psychology Today, Singularity Weblog, Standpoint Magazine, Swiss Monthly, Keep me Prime, and New Economy Magazine. Steve is one of three recipients of the 2020 H+ Innovator Award and shares this honour with Mirko Ranieri – Google AR and Dinorah Delfin – Immortalists Magazine. The H+ Innovator Award looks into our community and acknowledges ideas and projects that encourage social change, achieve scientific accomplishments, technological advances, philosophical and intellectual visions, author unique narratives, build fascinating artistic ventures, and develop products that bridge gaps and help us to achieve transhumanist goals. Steve has a background in project management and administration which has helped him to build a united team for effective fundraising and content creation, while his additional knowledge of biology and statistical data analysis allows him to carefully assess and coordinate the scientific groups involved in the project.

Related Organizations

Articles from this author

Reason Interview
Repair Biotechnologies, a company based in Syracuse, New York, has announced findings from early research suggesting that its technology can quickly stop the advancement of atherosclerosis. While these preclinical results are in mice, this approach has the potential for treating atherosclerosis in humans. In March, the company announced that it had received positive feedback from...
Editorial
Spring is in the air if you are in the Northern Hemisphere, and in the theme of new growth, let’s see what the Lifespan.io team has been up to recently. Happy Birthday to Lifespan.io Today, March 21st, it is our birthday, and we celebrate 10 years of supporting rejuvenation research. Lifespan.io President Keith Comito said,...
Biotech investment
Maximon, Marcuard Heritage, and GenTwo have announced the launch of a new longevity-related investment opportunity. Their proposal allows professional investors to get access to Maximon's portfolio of longevity companies via an actively managed certificate (AMC). According to Maximon, there have been many requests to launch an AMC focused on longevity. Therefore, Marcuard Heritage, a top...
Rejuvenate Biomed
Rejuvenate Biomed has recently concluded a clinical trial for sarcopenia. The results have shown “meaningful improvements in muscle strength, function and fatigue resistance”. What is sarcopenia? Sarcopenia is an age-related progressive loss of muscle mass and strength that affects many older adults. This decline in muscle mass and strength can greatly impact quality of life...
Old dog
Rejuvenate Bio has announced a partnership with a leading animal health company to develop a gene therapy for canine osteoarthritis. The identity of the partnering global company is as yet unknown. This San Diego-based biotech was co-founded in 2017 by Professor George Church of Harvard Medical School. It is focused on dog longevity research and...
Matthew O'Connor Interview
Cyclarity Therapeutics is developing an affordable, plaque-busting small molecule that may be the cure for the world's number one killer: cardiovascular disease. With human trials planned for this year, we decided that it was time to catch up with Cyclarity and its CEO of Scientific Affairs, Dr. Matthew O’Connor, to see how things were going....